子宮腺肌癥細(xì)胞系 BioVector NTCC質(zhì)粒載體菌種細(xì)胞基因保藏中心
- 價(jià) 格:¥98965
- 貨 號(hào):Adenomyosis cell line
- 產(chǎn) 地:北京
- BioVector NTCC典型培養(yǎng)物保藏中心
- 聯(lián)系人:Dr.Xu, Biovector NTCC Inc.
電話:400-800-2947 工作微信:1843439339 (QQ同號(hào))
手機(jī):18901268599
地址:北京
- 已注冊(cè)
子宮腺肌癥細(xì)胞系
Adenomyosis remains an enigmatic disease in the clinical and research communities. The high prevalence, diversity of morphological and symptomatic presentations, array of potential etiological explanations, and variable response to existing interventions suggest that different subgroups of patients with distinguishable mechanistic drivers of disease may exist. These factors, combined with the weak links to genetic predisposition, make the entire spectrum of the human condition challenging to model in animals. Here, after an overview of current approaches, a vision for applying physiomimetic modeling to adenomyosis is presented. Physiomimetics combines a system's biology analysis of patient populations to generate hypotheses about mechanistic bases for stratification with in vitro patient avatars to test these hypotheses. A substantial foundation for three-dimensional (3D) tissue engineering of adenomyosis lesions exists in several disparate areas: epithelial organoid technology; synthetic biomaterials matrices for epithelial–stromal coculture; smooth muscle 3D tissue engineering; and microvascular tissue engineering. These approaches can potentially be combined with microfluidic platform technologies to model the lesion microenvironment and can potentially be coupled to other microorgan systems to examine systemic effects. In vitro patient-derived models are constructed to answer specific questions leading to target identification and validation in a manner that informs preclinical research and ultimately clinical trial design.
Supplier來(lái)源:BioVector NTCC Inc.
TEL電話:400-800-2947
Website網(wǎng)址: http://www.nedfriskphoto.com
您正在向 biovector.net 發(fā)送關(guān)于產(chǎn)品 子宮腺肌癥細(xì)胞系 BioVector NTCC質(zhì)粒載體菌種細(xì)胞基因保藏中心 的詢問(wèn)
- 公告/新聞




